These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37269983)

  • 21. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival.
    Tudela-Lerma M; Orcajo-Rincón J; Ramón-Botella E; Álvarez-Luque A; González-Leyte M; Rotger-Regi A; Velasco-Sánchez E; Colón-Rodríguez A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(2):82-90. PubMed ID: 33239249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison.
    Agirrezabal I; Bouattour M; Pinato DJ; D'Alessio A; Brennan VK; Carion PL; Shergill S; Amoury N; Vilgrain V
    Eur J Cancer; 2024 Jan; 196():113427. PubMed ID: 37988840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma.
    Li Q; Wang X; Li D; Liu Y; Liu K; Liang J; Sun J; Jiang Q; Li J; Liu Z; Gong J; Xiang L; Jia Z; Chen Z; Cao M; Jiang Y
    J Vis Exp; 2024 May; (207):. PubMed ID: 38856215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up.
    Weissinger M; Vogel J; Kupferschläger J; Dittmann H; Castaneda Vega SG; Grosse U; Artzner C; Nikolaou K; la Fougere C; Grözinger G
    PLoS One; 2020; 15(12):e0244235. PubMed ID: 33378338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-CT post therapy dosimetry in radioembolization with resin
    Richetta E; Pasquino M; Poli M; Cutaia C; Valero C; Tabone M; Paradisi BP; Pacilio M; Pellerito RE; Stasi M
    Phys Med; 2019 Aug; 64():16-23. PubMed ID: 31515015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
    Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
    Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study.
    Miller MD; Sze DY; Padia SA; Lewandowski RJ; Salem R; Mpofu P; Haste PM; Johnson MS
    J Vasc Interv Radiol; 2018 Jun; 29(6):867-873. PubMed ID: 29724518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of transarterial radioembolization with Yttrium-90 glass microspheres without cystic artery occlusion.
    Topcuoglu OM; Alan Selcuk N; Sarikaya B; Toklu T
    Radiol Med; 2019 Jun; 124(6):575-580. PubMed ID: 30635753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer.
    Ridouani F; Soliman MM; England RW; Hsu M; Moskowitz CS; Doustaly R; Sofocleous CT; Boas FE; Yarmohammadi H; Deipolyi AR
    Eur J Radiol; 2021 Mar; 136():109539. PubMed ID: 33476965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors.
    Sharma NK; Kappadath SC; Chuong M; Folkert M; Gibbs P; Jabbour SK; Jeyarajah DR; Kennedy A; Liu D; Meyer JE; Mikell J; Patel RS; Yang G; Mourtada F
    Brachytherapy; 2022; 21(5):569-591. PubMed ID: 35599080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases.
    Morsbach F; Pfammatter T; Reiner CS; Fischer MA; Sah BR; Winklhofer S; Klotz E; Frauenfelder T; Knuth A; Seifert B; Schaefer N; Alkadhi H
    Invest Radiol; 2013 Nov; 48(11):787-94. PubMed ID: 23748229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.